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Objectives Overcoming racial differences in acute coronary syndrome (ACS) outcomes is a strategic goal for U.S. health
care. Genetic polymorphisms in the adrenergic pathway seem to explain some outcome differences by race in
other cardiovascular diseases treated with -adrenergic receptor blockade (BB). Whether these genetic variants
are associated with survival among ACS patients treated with BB, and if this differs by race, is unknown.
Background -adrenergic receptor blockade after ACS is a measure of quality care, but the effectiveness across racial groups
is less clear.
Methods A prospective cohort of 2,673 ACS patients (2,072 Caucasian; 601 African-American) discharged on BB from
22 U.S. hospitals were followed for 2 years. Subjects were genotyped for polymorphisms in ADRB1, ADRB2,
ADRA2C, and GRK5. We used proportional hazards regression to model the effect of genotype on mortality,
stratified by race and adjusted for baseline factors.
Results The overall 2-year mortality rate was 7.5% for Caucasians and 16.7% for African Americans. The prognosis asso-
ciated with different genotypes in these BB-treated patients differed by race. In Caucasians, ADRA2C 322-325
deletion carriers had significantly lower mortality as compared with homozygous individuals lacking the deletion
(hazard ratio: 0.46; confidence interval [CI]: 0.21 to 0.99; p  0.047; race  genotype interaction p  0.053). In
African Americans, the ADRB2 16R allele was associated with significantly increased mortality (hazard ratio for
RG vs. GG: 2.10; CI: 1.14 to 3.86; RR vs. GG: 2.65; CI: 1.38 to 5.08; p  0.013; race  genotype interaction
p  0.096).
Conclusions Adrenergic pathway polymorphisms are associated with mortality in ACS patients receiving BB in a race-specific man-
ner. Understanding the mechanism by which different genes impact post-ACS mortality differently in Caucasians and
African Americans might illuminate opportunities to improve BB therapy in these groups. (J Am Coll Cardiol 2012;
60:898–907) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.051More than 1.6 million patients are hospitalized in North
America each year with acute coronary syndrome (ACS)
(acute myocardial infarction [MI] or unstable angina [UA])
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2012, accepted February 27, 2012.(1). Evidence-based practice guidelines, developed jointly by
the American Heart Association and American College of
Cardiology, recommend that -blocker (BB) therapy be
initiated in all patients without a contraindication (2,3), and
administration of BB after MI is an accepted performance
measure of high-quality health care (4). These recommen-
dations are based on results of older trials with less diverse
cohorts, whereas subsequent larger studies in other racial
groups (5) as well as meta-analyses (6) have questioned the
consistency of BB benefit across the spectrum of MI
patients, with the potential for hazard observed in at least 1
study (5). It has been hypothesized that a portion of this
variability might be due to genetic variation, which is of
particular interest, given the intersection of race with
genetics and the disparities in ACS outcomes in the United
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September 4, 2012:898–907 Adrenergic Variants and Survival After ACSStates (7). Identifying genetic predictors of BB-related
outcomes in ACS patients could allow more targeted
prognostic risk estimates and, hopefully, support more
appropriate use of therapy to reduce the public health
burden of ACS and heterogeneity of outcomes.
Support for genetic variation contributing to differences
in BB response is available in the case of systolic heart
failure, where although BBs are a cornerstone of standard
therapy due to their overall mortality benefit (8–10), sub-
stantial heterogeneity of individual responses—related in
part to genetic sequence variants in the adrenergic path-
way—have been documented (11–13). For example, func-
tional genetic variants within genes encoding the
-adrenergic receptor 1 (ADRB1 R389G; rs1801253), the
-adrenergic receptor 2 (ADRB2 G16R; rs1042713 and
ADRB2 Q27E; rs1042714), the alpha-2c receptor (ADRA2C
322-325 deletion; rs2234888), and—more recently—G-
protein receptor kinase 5 (GRK5 L41Q; rs17098707), a
critical regulator of -receptor function, are associated with
BB response in heart failure (13–18). These data raise the
question as to whether functional adrenergic genetic vari-
ants might influence BB-related outcomes after ACS.
Consistent with this notion is our previous work, from an
exploratory analysis of a small ACS cohort, which suggested
an association of ADRB2 genotypes with survival in patients
reated with BB (19). However, this study was inadequately
owered to accurately define the importance of each variant
ithin racial subgroups. That most of the candidate variants
iffer in allele frequency in Caucasians, as compared with
frican Americans, underscores the importance of defining
ace-specific associations between genetic variants and out-
omes. To address this existing gap in knowledge, we report
he results of a large, prospective, longitudinal analysis of
he effect of genetic variants on mortality in patients who
uffered an ACS and were treated with BB, stratified by
ace. This analysis represents the first comprehensive study
f previously reported functional adrenergic pathway genetic
ariants in an ACS cohort.
ethods
ubjects. Between March 2001 and December 2008, 8,037
atients with ACS (7,517 acute MI, 520 UA) from 31 U.S.
ospitals were prospectively screened and enrolled into 3
onsecutive observational cohort studies: 1) the INFORM
INvestigation oF Outcomes from acute coronary syndRoMes)
tudy (n 1,199) from March 2001 to October 2002; 2) the
PREMIER (Prospective Registry Evaluating outcomes af-
ter Myocardial Infarction: Events and Recovery) study (n 
2,498) from January 2003 to June 2004; and 3) the
TRIUMPH (Translational Research Investigating Under-
lying disparities in acute Myocardial infarction Patients’
Health status) study (n  4,340) from April 2005 to
December 2008, as previously described (19–22). The MI
patients were identified by an elevated troponin blood test
and either diagnostic electrocardiogram changes or ischemic asymptoms. The UA patients had
a normal troponin but presented
with electrocardiogram changes
(left bundle branch block 4%, ST-
segment elevations 9%, ST-segment
depression 12%, T-wave inversions
22%) and cardiac symptoms, de-
fined as new-onset angina (2
months) of at least Canadian
Cardiovascular Society Classifi-
cation class III, prolonged (20
min) rest angina, recent (2
months) worsening of angina, or
angina that occurred within 2 weeks of a previous MI (23).
To further increase the specificity of the UA diagnosis,
those patients with a diagnostic study that excluded obstruc-
tive coronary disease (e.g., coronary angiography, nuclear or
echocardiographic stress testing) (n  125) or confirmed an
alternative explanation for their presentation (e.g., esopha-
gogastroduodenoscopy) were excluded. Three physicians
adjudicated the charts of those patients with diagnostic
uncertainty (n  45) and attained consensus on the final
iagnosis.
Within these combined cohorts, a subset of 3,373 pa-
ients were approached for and consented to genetic testing
nd were genotyped for adrenergic pathway polymorphisms.
he genetics cohort was representative of the entire cohort
24). Of these, 2,946 (87%) were discharged alive on BB
nd were included in the present analyses. We further
xcluded 94 patients who were either transferred to other
ospitals or who left against medical advice because their
se of BB at discharge could not be definitively ascertained.
inally, given the large frequency differences for several
enotypes of interest across race, we restricted the analyses
o self-identified Caucasian and African-American patients,
ielding a final sample size of 2,673 patients (2,469 MI; 204
A; 2,072 Caucasians; 601 African Americans) from 22
enters.
Each patient was prospectively interviewed during hos-
ital stay to ascertain their sociodemographic (including
elf-identified race), economic, and health status character-
stics. Detailed chart abstractions were performed to obtain
edical history of patients, laboratory results, disease sever-
ty, and the processes of inpatient care. All 3 studies received
nstitutional review board approval at all participating sites,
nd written informed consent was obtained from each
articipant.
ortality assessment. The Social Security Administration
eath Master File was queried to determine vital status of
atients as of December 30, 2009, and was available for all
atients in this study.
enotyping. Deoxyribonucleic acid (DNA) was isolated
nd purified from whole blood with the Qiagen QIAamp
NA purification kit (Quiagen, Germantown, Maryland).
he DNA segments containing the region of interest were
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
BB  -adrenergic receptor
blockade
CI  confidence interval
HR  hazard ratio
I/D  insertion/deletion
MI  myocardial infarction
UA  unstable anginamplified with the polymerase chain reaction (PCR). The
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(25), and pyrosequencing primers were designed with the
Pyrosequencing SNP Primer Design software (version 1.01,
QIAGEN, Hilden, Germany). Before use, PCR primer
sequences were screened across the human genome with the
National Center for Biotechnology Information Basic Local
Alignment Search Tool program to ensure their specificity
for the gene of interest. The PCR was carried out with
Amplitaq Gold PCR master mix (ABI, Foster City, Cali-
fornia), 1 pmol of each primer (IDT, Coralville, Iowa), and
1 ng of DNA. The PCR primers and conditions are listed
in Online Table S1. Pyrosequencing was performed with
the PSQ HS 96A system with MA v2.0 software (Qiagen,
Kungsgatan, Germany), as previously described (26). Data
were automatically transferred from the PSQ HS 96A to a
Microsoft Access (Richmond, Washington) database for
permanent storage and merging with the clinical datasets
through SAS (version 9.1, SAS, Cary, North Carolina).
Statistical analyses. Baseline and follow-up characteristics
were compared by genotype. Categorical data are reported
as frequencies, and differences between groups were com-
pared with chi-square or Fisher exact tests, as appropriate.
Continuous data are reported as mean  SD, and differ-
ences between groups were tested with 1-way analysis of
variance. Hardy-Weinberg equilibrium was assessed with
chi-square test or Monte Carlo permutation with 10,000
iterations, as appropriate. Kaplan-Meier estimates and Cox
proportional hazards models were used to describe the effect
of genotype on patient survival. A dominant model was used
for ADRA2C 322-325 deletion and GRK5 L41Q genotypes
due to the low minor allele frequencies of these variants. For
all other genotypes, we used an additive model. Follow-up
began at the time of discharge from the index hospital stay.
Stratified proportional hazards models were used, adjusting
for study and site. To estimate the independent contribution
of genotype, after adjusting for potential confounders and
other clinical predictors, the proportional hazards models
included covariates that were thought to be clinically im-
portant (age, sex, type of ACS, hypertension, diabetes, heart
failure, chronic obstructive pulmonary disease, coronary
angiography, and coronary revascularization) as well as
those that differed significantly by genotype (Online Tables
S1 to S4). To mitigate the possibility of “over fitting,” we
also tested models adjusted for age and sex only, for the
variants that had significant associations (minimally ad-
justed model) (Online Table S6); these were consistent with
the results of the primary analysis.
Analyses were performed separately in Caucasians and
African Americans to minimize the risk of false-positive
findings due to population stratification. We further as-
sessed the issue of population stratification with a subgroup
of 492 TRIUMPH subjects (382 Caucasian; 110 African-
American) who were genotyped as part of a separate project
with a custom array containing 3,351 single nucleotide
polymorphisms and 100 ancestry informative markers
(27,28). With these single nucleotide polymorphisms, weestimated 10 principal components with Eigenstrat and
repeated our analyses in this subgroup to assess whether
population stratification impacted our findings. Including
principal components in the model did not meaningfully
alter the findings, providing support for our categorization
of race. For primary effects, p values 0.05 were considered
statistically significant (29). Analyses were performed with
SAS (version 9.2, SAS) and R (version 2.11.1) (30).
Results
Baseline characteristics of the cohort, stratified by race, are
shown in Table 1. Types of BBs prescribed at discharge are
shown in Table 2. Of the cohort, 91.6% was discharged on
either metoprolol (82%; mean dose 73  58 mg/day) or
arvedilol (9.6%; mean dose 18  14 mg/day); dose distri-
ution is shown in Table 3. The 2-year mortality rate was
.5% for Caucasians (n  152) and 16.7% for African
mericans (n  96). We genotyped the study subjects for
unctionally significant polymorphisms within the adrener-
ic pathway that have been previously linked to outcomes
fter BB use, specifically variants within the genes encoding
-adrenergic receptors 1 (ADRB1) and 2 (ADRB2),
alpha-2c adrenergic receptor (ADRA2C), and G-protein
receptor kinase 5 (GRK5). For all variants, genotype call
rates were 96%. Variants, genotype frequencies in Cau-
casians and African Americans, and the test of Hardy-
Weinberg equilibrium are shown in Table 4. Consistent
with prior reports, GRK5 L41 and ADRA2C deletion allele
frequencies were much higher among African Americans as
compared with Caucasians (15). The frequencies of the
other genotypes examined were similar to those previously
reported (31).
Among the 2,072 Caucasian subjects, 2-year mortality
differences across genotypes were assessed with Kaplan-
Meier estimates (Figs. 1 to 4A) and proportional hazards
regression modeling (Fig. 5) with adjustment for a priori
selected baseline characteristics and clinical characteristics
that differed significantly between genotype groups (Online
Tables S1 to S5). The ADRA2C 322-325 insertion/deletion
I/D) genotype was significantly associated with 2-year
ortality among Caucasians in the adjusted analyses (haz-
rd ratio [HR]: 0.46; confidence interval [CI]: 0.21 to 0.99;
 0.047) with ADRA2C ID and ADRA2C DD (i.e.,
eletion carriers) subjects having greater survival compared
ith ADRA2C II homozygous individuals. By contrast,
one of the other genetic variants tested were significantly
ssociated with 2-year mortality among Caucasians in either
djusted or unadjusted analyses (all p  0.3).
In similarly constructed models, the association of each
olymorphism with mortality was tested in a total of 601
frican Americans (Figs. 1 to 4B and 5). Although neither
he ADRB1 nor ADRA2C variants were associated with
ortality (p  0.5), ADRB2 variants were. The ADRB2
G16R variant was significantly associated with mortality
among BB-treated African Americans in both unadjusted
ment e
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September 4, 2012:898–907 Adrenergic Variants and Survival After ACSand adjusted analyses. Compared with African-American
ADRB2 G16 allele homozygous individuals treated with
BB, ADRB2 R16 allele carriers had greater mortality in both
unadjusted (RG vs. GG HR: 1.74; CI: 0.96 to 3.16; RR vs.
GG HR: 2.25; CI: 1.21 to 4.21; p  0.039) (Fig. 3B) and
fully adjusted analyses (RG vs. GG HR: 2.10; CI: 1.14 to
3.86; RR vs. GG HR: 2.65; CI: 1.38 to 5.08; p 0.013) (Fig. 5).
Notably, patients homozygous for the R allele had the greatest
risk, and heterozygous patients had an intermediate risk, consis-
Patient Characteristics by RaceTable 1 Patient Characteristics by Race
White/Caucasian (n  2
Age, yrs 59.8 12.3
Sex
Male 1,476 (71.2%)
Female 596 (28.8%)
BMI, kg/m2 29.4 6.0
Smoking status
Current (30 days) 782 (37.9%)
Former (30 days) 702 (34.0%)
Never (or 100 total) 580 (28.1%)
Dyslipidemia 1,072 (51.7%)
Hypertension 1,255 (60.6%)
Diabetes 518 (25.0%)
Prior PCI 457 (22.1%)
Prior CABG 275 (13.3%)
Prior MI 414 (20.0%)
Peripheral arterial disease 109 (5.3%)
Prior CVA 67 (3.2%)
Prior TIA 47 (2.3%)
Chronic heart failure 109 (5.3%)
Chronic renal failure 74 (3.6%)
Chronic lung disease 154 (7.4%)
LV systolic function
Normal 1,178 (57.7%)
Mild 458 (22.4%)
Moderate 288 (14.1%)
Severe 117 (5.7%)
Diseased vessels
0 101 (5.1%)
1 818 (41.6%)
2 562 (28.6%)
3 485 (24.7%)
ACS type
STEMI 1,006 (48.6%)
NSTEMI 912 (44.0%)
UA 154 (7.4%)
BB on arrival 638 (30.8%)
GRACE risk score 97.9 29.1
Revascularization type
None 377 (18.2%)
PCI 1,513 (73.0%)
CABG 182 (8.8%)
Values are mean  SD or n (%).
ACS  acute coronary syndrome(s); BB -adrenergic receptor blockad
cardiovascular accident; GRACE  Global Registry of Acute Coronary E
infarction; PCI  percutaneous coronary intervention; STEMI  ST-seg
unstable angina.tent with a gene–dose effect.Because our pilot data suggested that both of the ADRB2
variants (ADRB2 G16R and ADRB2 Q27E)—which are in
linkage disequilibrium—might contribute to BB-related
outcomes, we retested the mortality association of the
compound genotype that most strongly correlated with risk
in this earlier study. Among African Americans treated with
BB, the results were similar to our pilot data, whereas this
was not the case in Caucasians (Fig. 4). In adjusted analyses
among African Americans, the compound genotype was
Black/African-American (n  601) p Value
56.9 11.9 0.001
0.001
324 (53.9%)
277 (46.1%)
30.0 7.3 0.043
0.001
273 (45.9%)
148 (24.9%)
174 (29.2%)
262 (43.6%) 0.001
463 (77.0%) 0.001
246 (40.9%) 0.001
94 (15.6%) 0.001
52 (8.7%) 0.002
147 (24.5%) 0.018
29 (4.8%) 0.671
44 (7.3%) 0.001
9 (1.5%) 0.245
110 (18.3%) 0.001
106 (17.6%) 0.001
59 (9.8%) 0.057
0.001
367 (61.8%)
89 (15.0%)
51 (8.6%)
87 (14.6%)
0.001
82 (17.5%)
192 (41.0%)
96 (20.5%)
98 (20.9%)
0.001
166 (27.6%)
385 (64.1%)
50 (8.3%)
224 (37.3%) 0.003
100.7 30.1 0.043
0.001
308 (51.2%)
254 (42.3%)
39 (6.5%)
body mass index; CABG coronary artery bypass graft surgery; CVA
V  left ventricular; NSTEMI  non–ST-segment elevation myocardial
levation myocardial infarction; TIA  transient ischemic attack; UA ,072)
e; BMI
vents; Lassociated with a 6-fold risk of mortality in the high-risk
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group (Fig. 5) (p  0.048).
In African Americans, the GRK5 Q41L variant had a
orderline-significant association with mortality in adjusted
nalyses. Although not achieving statistical significance, the
RK5 L41 African-American patients treated with BB
rended toward lower mortality as compared with homozy-
ous GRK5 Q41 patients (adjusted HR: 0.68; CI: 0.45 to
.04; p  0.07). We also tested for but found no significant
ene-gene interaction between ADRB2 and GRK5 and
outcomes in African-American ACS patients (interaction p
value between ADRB2 G16R and GRK5 Q41L  0.86).
Because each of the 2 sequence variants that showed a
significant survival association did so in only 1 racial group,
we performed formal interaction tests to further assess the
significance of the racial distinction. The race  genotype
interaction approached significance for both ADRA2C I/D
(p  0.053) and ADRB2 G16R (p  0.096).
Discussion
In accordance with consensus guidelines and quality perfor-
mance measures, it is recommended that all patients with-
out contraindications be discharged on BB therapy after MI
(4,32–34). However, the consistent efficacy of BB in all
groups has been questioned, and this variability might be
related in part to genetic heterogeneity (5,6). Our data
suggest that variability in post-ACS outcomes among BB-
treated patients is associated with genetic variation in the
adrenergic pathway. Importantly, we identified different
prognostically important genes in African Americans, as
compared with Caucasians. Specifically, the ADRA2C I/D
genotype was significantly associated with 2-year mortality
in post-ACS Caucasians treated with BB, whereas the
ADRB2 G16R and GRK5 Q41L genotypes were associated
with 2-year mortality in post-ACS African Americans
treated with BB. These findings suggest that race-specific
adrenergic-pathway variants might be useful in defining
prognosis after BB therapy for Caucasians and African-
BB on DischargeTable 2 BB on Discharge
Metoprolol 2,193 (82.0%)
Carvedilol 256 (9.6%)
Atenolol 191 (7.1%)
Labetalol 19 (0.7%)
Sotalol 8 (0.3%)
Nadolol 3 (0.1%)
Propranolol 3 (0.1%)
Pindolol 2 (0.1%)
Betaxolol 1 (0.0%)
Bisoprolol 1 (0.0%)
BB not recorded 14 (0.5%)
Total 2,673 (100%)
Values are n (%).
BB  -adrenergic receptor blockade.American ACS patients.It is important to note that the race specificity of our
findings is not due to differences in allele frequency. For
example, although the ADRA2C D allele is much more
common in African Americans, there was no risk relation-
ship between this gene and mortality in these patients,
whereas it was associated with risk in Caucasians (race 
enotype interaction p  0.053). This contrasts with our
re-study hypothesis that this allele likely would have
imilar effects regardless of race. Our data suggest some-
hing more complex: that the allele effects might be specific
o the Caucasian genetic environment. This is a novel
bservation requiring replication. If verified in other popu-
ations, then mechanistic studies are needed to understand
hether ancestry-specific linkage or other genetic modifiers
ight explain the observed differences in allelic associations
cross race.
Beyond the prognostic difference between races, the
ssociation of the ADRA2C I/D variant with 2-year mor-
ality in Caucasian patients discharged on BB is the first
eport of this finding in ACS patients. ADRA2C D creates
hypo-functioning form of this presynaptic inhibitory
eceptor, which has been previously associated with in-
reased catecholamine release in vitro (35) and in vivo (36).
onsistent with this, the ADRA2C D allele has also been
reviously associated with increased risk of heart failure
35). Our findings could be consistent with this line of
vidence, considering that patients with the ADRA2C D
llele might have a higher adrenergic state and thus display
nhanced benefit from BB (37), potentially resulting in the
ower mortality we observed when comparing genotype
roups treated with BB. Conversely, our findings contrast
ith recent observations in heart failure patients where the
B bucindolol provided survival benefit in ADRA2C II
Dose Distribution ofMetoprolol and Carvedilol on DischargeTable 3 Dose Distribution ofMetoprolol and Carvedilol on Discharge
Dose (mg/day) %
Carvedilol
3.125 6.25
6.25 23.75
12.5 32.08
25 25.42
50 12.08
62.5 0.42
Metoprolol
12.5 2.49
25 22.06
37.5 0.23
50 39.52
75 1.93
100 21.97
112.5 0.05
125 0.05
150 3.36
200 6.86
300 0.83400 0.64
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bly due to enhanced sympatholysis in ADRA2C D carriers
18). This inconsistency might be attributable to differences
etween the pathophysiologic role of adrenergic signaling in
CS patients as compared with heart failure. For example,
t has been proposed that sympatholysis might be particu-
arly detrimental in heart failure patients (38). Alternatively,
he inconsistency could be due to pharmacological differ-
nces in the specific agents used (no bucindolol in the
resent study [Table 2] vs. 100% bucindolol use in BEST
Beta-Blocker Evaluation of Survival Trial]), especially
iven that bucindolol is unique among BB agents for
ausing sympatholysis. Our findings warrant further in-
estigation of the role of genetic variation in ADRA2C
nd the possible variability by type of BB agent, in
aucasian ACS patients.
Genotype Frequencies and HW p ValuesTable 4 Genotype Frequencies and HW p Va
SNP Genotype
% Frequency
Caucasian
ADRA2C INDEL II 90.46
ID 8.99
DD 0.55
ADRB1 R389G RR 52.85
RG 38.63
GG 8.52
ADRB2 G16R GG 37.01
GR 48.24
RR 14.75
ADRB2 Q27E QQ 34.39
QE 49.33
EE 16.28
GRK5 Q41L QQ 96.50
QL 3.35
LL 0.15
HW  Hardy-Weinberg equilibrium; SNP  single nucleotide polymor
Figure 1 Kaplan-Meier Curves of ADRA2C Insertion/Deletion E
(A) Caucasian -blocker–treated acute coronary syndrome (ACS) subjects stratified
jects stratified by ADRA2C deletion carrier status.Beta-adrenergic receptor signaling is down-regulated by
-protein receptor kinases (GRKs) (39). The GRK 5
hosphorylates, uncouples, and internalizes 1-adrenergic
eceptors, and the GRK5 L41 variant has greater activity
han the GRK5 Q41 variant for all of these functions (15).
e previously described a pharmacogenomic effect of
RK5 in subjects with ACS (15). The GRK5 Q41L
olymorphism was previously found to be a determinant of
-blocker responsiveness in heart failure among African
Americans, with a protective -blocker–mimetic effect seen
in GRK5 L41 allele carriers (13). Similarly, we found a
strong trend toward improved outcomes in post-ACS
African-American patients carrying this allele. Our findings
are also consistent with our previous observations in heart
failure patients in terms of the magnitude of effect: roughly
one-half the mortality risk as compared with the GRK5
HW
p Value
% Frequency
African Americans
HW
p Value
0.2033 38.63 0.0334
42.51
18.85
0.1747 34.77 0.2237
50.43
14.80
0.5009 23.84 0.6096
48.89
27.27
0.3663 67.98 0.3525
28.25
3.77
0.3427 54.99 0.2403
37.06
7.95
on Post-ACS 2-Year Survival
RA2C deletion carrier status. (B) African-American -blocker–treated ACS sub-luesffect
by AD
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significance, with a similar effect size, likely reflects subop-
timal power for this particular analysis as well as our
inability to contrast BB-treated patients with those not
treated with BB (due to the near universal compliance with
BB as a performance measure of quality in ACS).
In this study, the ADRB2 G16R genotype was signifi-
cantly associated with mortality in African-American ACS
patients, such that patients homozygous for the R allele had
greatest risk and heterozygous patients had an intermediate
risk, consistent with a gene–dose effect and our previous
findings (19). There was an even greater stratification in risk
when both functional G16R and Q27E ADRB2 variants
were accounted for, showing approximately a 4-fold and
6-fold risk in the intermediate- and high-risk groups,
respectively. However, unlike our pilot data, in which the
association was found in a much smaller cohort that
Figure 2 Kaplan-Meier Curves of GRK5 Gln/Leu 41 Effect on P
(A) Caucasian -blocker–treated acute coronary syndrome (ACS) subjects stratified
stratified by GRK5 41Leu carrier status.
Figure 3 Kaplan-Meier Curves of ADRB2 G16R Effect on Post-A
(A) Caucasian -blocker–treated acute coronary syndrome (ACS) subjects stratified
fied by ADRB2 G16R status.included both African-American and Caucasian patients,
our current analysis suggests that the association is specific
to African Americans. Due to this distinction, the ADRB2
association is not a strict validation and requires confirma-
tion in additional, adequately sized, cohort(s) of African-
American ACS patients. Nonetheless, these data extend
previous reports and are the first description, to our knowl-
edge, of an African-American–specific effect of ADRB2
genotype in ACS patients. Conversely, the lack of associa-
tion in Caucasians is strong, suggesting that additional
inquiry into this association is unlikely to reveal a strong
effect of ADRB2 genotype among Caucasian ACS patients
treated with BB.
Study limitations. Our study should be interpreted in the
context of several potential limitations. First, due to the
high level of adherence to guidelines recommendations,
only a small number of subjects were not treated with BB.
CS 2-Year Survival
RK5 41Leu carrier status. (B) African-American -blocker–treated ACS subjects
-Year Survival
RB2 G16R status. (B) African-American -blocker–treated ACS subjects strati-ost-A
by GCS 2
by AD
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genotype with BB treatment. Thus, we cannot specifically
comment on BB efficacy, and have focused solely on the
genetic association with outcomes in BB-treated patients.
In light of these data, however, it might be worthwhile to
consider a randomized trial of BB in the genetic subgroups
Figure 4 Kaplan-Meier Curves of ADRB2 Composite Genotype E
(A) Caucasian -blocker–treated acute coronary syndrome (ACS) subjects stratified
subjects stratified by ADRB2 composite genotype status. ADRB2 composite genot
allele; (C) subjects homozygous for both ADRB2 R16 allele and ADRB2 Q27 allele
Figure 5 Model-Adjusted Hazard Ratios for 2-Year All-Cause Mo
ADRB2 composite genotype as in Figure 4.that show poor outcomes with BB therapy in order to exclude
the possibility of harm from BB treatment. Alternatively, new
study approaches such as using quantified drug exposure
metrics (as opposed to simply present vs. absent) or identifi-
cation of a non-U.S. cohort of ACS patients where BB
treatment is less common might show greater variability in
on Post-ACS 2-Year Survival
RB2 composite genotype status. (B) African-American -blocker–treated ACS
follows: (A) subjects homozygous for both ADRB2 G16 allele and ADRB2 E27
ubjects heterozygous for ADRB2 G16R and/or ADRB2 Q27E.
yffect
by AD
ype as
; (B) srtalit
m
c
t
A
a
h
a
a
p
s
w
t
s
m
h
C
I
a
a
s
B
A
a
h
A
t
h
g
s
m
A
B
m
t
906 Cresci et al. JACC Vol. 60, No. 10, 2012
Adrenergic Variants and Survival After ACS September 4, 2012:898–907BB use (i.e., more subjects off BB) and allow drug 
genotype interaction analyses. Despite this inherent limita-
tion, our findings are important, because they identify
genetic subgroups with worse outcomes despite BB treat-
ment and in whom more aggressive interventions to im-
prove mortality might be warranted. An additional limita-
tion is that we had insufficient sample size to differentiate
between BB agents, and thus agent-specific effects are not
obtainable from this study. A third limitation is that the
current study includes 735 subjects previously described in
our preliminary analysis testing the hypothesis that ADRB1
and ADRB2 polymorphisms would be associated with
ortality in BB-treated patients (19). However, in the
urrent study, we have increased the total cohort by more
han 4-fold (including a quadrupling of the African-
merican population), enabling us to examine race-specific
ssociations between genetic variation and mortality. We
ave also included additional published variants in our
nalysis (GRK5 and ADRA2C), enabling a more complete
nalysis of genes within the adrenergic pathway, and have
erformed analyses that provide evidence that population
tratification is not confounding our findings. Finally, we
ere not able to account for changes in medications over
ime. However, classifying patients by discharge medication
tatus is a well-recognized and often-used approach, because
ost patients remain on their discharge regimen after
ospital stay (40).
onclusions
n summary, our findings represent the first comprehensive
nalysis of established functional genetic variants within
drenergic pathway genes in an ACS cohort and show that
everal of these variants are associated with mortality among
B-treated patients and that these associations vary by race.
mong Caucasian patients that have suffered an ACS and
re treated with BB, ADRA2C II homozygous individuals
ad increased mortality as compared with ADRA2C ID and
DRA2C DD subjects. In African-American ACS patients
reated with BB, GRK5 L41 allele carriers trended toward
aving lower mortality compared with GRK5 Q41 homozy-
ous patients, whereas ADRB2 16R allele carriers had
ignificantly increased mortality in a gene–dose response
anner. Further study is needed to replicate our findings in
frican-American patients; randomized trials of post-ACS
B treatment in race-specific, genotype-defined subgroups
ight be warranted to insure the benefits of BB therapy in
hese high-risk individuals.
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